Literature DB >> 2429361

Analysis of bronchoalveolar lavage fluid from bleomycin-induced pulmonary fibrosis in hamsters.

S N Giri, D M Hyde, J M Nakashima.   

Abstract

The purpose of this study was to analyze the cellular and noncellular components of bronchoalveolar lavage fluid (BALF) at varying times during the development of pulmonary fibrosis induced by bleomycin. Hamsters were killed and lavaged in situ following the administration of a single intratracheal injection of 1 unit of bleomycin or an equivalent volume of sterile isotonic saline. The results show that the total cell counts in the BALF of bleomycin-treated hamsters, as compared with controls, were increased 7.7, 4.4, 2.4, 1.6, and 1.9-fold at 2, 4, 7, 14, and 21 days after treatment, respectively. The predominant cell types in the BALF of control animals were macrophages which constituted 84% of the total cells, followed by lymphocytes, 11%. The predominant cell types in the BALF of bleomycin-treated animals were polymorphonuclear leukocytes (PMN) which constituted 65% at two days and approximately 50% of the total at 4, 7, and 14 days; at 21 days macrophages were the predominant cell type constituting 50%, followed by lymphocytes at 30%. However, the total number of lymphocytes was not increased at 21 days compared to previous times. The noncellular protein content of BALF from bleomycin-treated hamsters, an index of pulmonary vascular permeability, was increased to 224, 559, 637, and 270% of control (2.7 mg/lung) at 2, 4, 7, and 14 days after treatment, respectively, and returned to control levels at 21 days. The acid phosphatase activity in the supernatant of BALF of bleomycin-treated animals was significantly increased to 181, 181, 199, 176, and 125% of control (258 units/lung) at 2, 4, 7, 14, and 21 days, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429361     DOI: 10.1177/019262338601400202

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  7 in total

1.  Ameliorating effect of an interferon inducer polyinosinic-polycytidylic acid on bleomycin-induced lung fibrosis in hamsters. Morphologic and biochemical evidence.

Authors:  S N Giri; D M Hyde
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

Review 2.  Modulators of inflammation in Bronchopulmonary Dysplasia.

Authors:  Rashmin C Savani
Journal:  Semin Perinatol       Date:  2018-10-02       Impact factor: 3.300

3.  Repeated episodes of C5a-induced neutrophil influx do not result in pulmonary fibrosis.

Authors:  J A Harris; D M Hyde; Q J Wang; M Y Stovall; S N Giri
Journal:  Inflammation       Date:  1991-06       Impact factor: 4.092

4.  Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice.

Authors:  S N Giri; D M Hyde; M A Hollinger
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

5.  Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis.

Authors:  Nurhayat Topaloğlu; Şehnaz Olgun Yıldızeli; Göksel Şener; Tunç Laçin; Özer Şehirli; Emine Bozkurtlar; Çiğdem Çelikel; Berrin Ceyhan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-09-16       Impact factor: 0.332

6.  Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.

Authors:  Xiao-xi Lv; Xiao-xing Wang; Ke Li; Zi-yan Wang; Zhe Li; Qi Lv; Xiao-ming Fu; Zhuo-wei Hu
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

7.  Amelioration of bleomycin-induced lung fibrosis in hamsters by dietary supplementation with taurine and niacin: biochemical mechanisms.

Authors:  S N Giri; R Blaisdell; R B Rucker; Q Wang; D M Hyde
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.